(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)
Why Valeo Pharma?
- Commercial stage revenue generating Canadian pharmaceutical company
- Approaching EBITDA positive in coming months
- 9 products currently marketed ($40M. estimated peak sales / year)
- 7 additional products in pipeline ($45M. estimated peak sales / year)
- In-license business model, no development or clinical risk
- $1.5M in quarterly revenue ending July 31, 2020
- $5.26M in revenue for 9 months ending July 31, 2020
Hub On AGORACOM / Corporate Profile
Visited 1 times, 1 visit(s) today
Last modified: July 27, 2026
